| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 07/30/2026 | ±2.6% | -3.0% | under-priced |
| 10/30/2025 | ±2.5% | -17.4% | under-priced |
| 07/31/2025 | ±3.0% | -10.2% | under-priced |
| 05/02/2025 | ±1.9% | -0.1% | over-priced |
| 10/31/2024 | ±2.0% | +0.6% | over-priced |
| 08/01/2024 | ±2.0% | -4.6% | under-priced |
| 05/02/2024 | ±1.4% | -3.5% | under-priced |
| 11/02/2023 | ±1.5% | +3.1% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $6.29 | $71.7B | $1.9B |
| Q1 FY2026 | $6.26 | $68.5B | $1.9B |
| Q4 FY2025 | $4.66 | $72.5B | $1.3B |
| Q3 FY2025 | $6.98 | $69.7B | $2.0B |
The Cigna Group (CI) reports in 115 days, with the next report estimated for 01/05/2027. Across the last 8 reports, options priced an average ±2.1% earnings move while the stock actually moved 5.3% on average — the market has tended to under-price CI's earnings risk. Fundamentals into the print: EPS up 10.2% year-over-year, revenue up 6.7%. QuantLogix's live 5-factor engine currently reads CI as a buy at 65/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →